- Home
- NCMI vs SVRA Comparison
NCMI vs SVRA Comparison
Compare NCMI & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- SVRA
- Stock Information
- Founded
- NCMI 2005
- SVRA 2007
- Country
- NCMI United States
- SVRA United States
- Employees
- NCMI N/A
- SVRA N/A
- Industry
- NCMI Advertising
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- NCMI Consumer Discretionary
- SVRA Health Care
- Exchange
- NCMI Nasdaq
- SVRA Nasdaq
- Market Cap
- NCMI 476.2M
- SVRA 528.3M
- IPO Year
- NCMI 2007
- SVRA N/A
- Fundamental
- Price
- NCMI $5.18
- SVRA $2.06
- Analyst Decision
- NCMI Strong Buy
- SVRA Buy
- Analyst Count
- NCMI 5
- SVRA 7
- Target Price
- NCMI $7.60
- SVRA $7.57
- AVG Volume (30 Days)
- NCMI 676.0K
- SVRA 2.5M
- Earning Date
- NCMI 08-04-2025
- SVRA 08-11-2025
- Dividend Yield
- NCMI 1.16%
- SVRA N/A
- EPS Growth
- NCMI N/A
- SVRA N/A
- EPS
- NCMI N/A
- SVRA N/A
- Revenue
- NCMI $238,300,000.00
- SVRA N/A
- Revenue This Year
- NCMI $10.10
- SVRA N/A
- Revenue Next Year
- NCMI $11.66
- SVRA N/A
- P/E Ratio
- NCMI N/A
- SVRA N/A
- Revenue Growth
- NCMI 42.10
- SVRA N/A
- 52 Week Low
- NCMI $4.12
- SVRA $1.89
- 52 Week High
- NCMI $7.60
- SVRA $5.11
- Technical
- Relative Strength Index (RSI)
- NCMI 46.50
- SVRA 34.43
- Support Level
- NCMI $5.15
- SVRA $2.13
- Resistance Level
- NCMI $5.35
- SVRA $2.49
- Average True Range (ATR)
- NCMI 0.21
- SVRA 0.15
- MACD
- NCMI 0.02
- SVRA -0.01
- Stochastic Oscillator
- NCMI 36.84
- SVRA 8.41
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.